http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109730966-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
| filingDate | 2019-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109730966-B |
| titleOfInvention | Chitosan oligosaccharide modified self-carried carrier-free nasal cavity nano preparation brain targeting delivery system and preparation method thereof |
| abstract | The invention discloses a chitosan oligosaccharide modified self-carried non-carrier nasal cavity nano preparation brain targeting delivery system and a preparation method thereof. Comprises hydrophobic micromolecular drugs with neuroprotective effect, polyethylene glycol derivatives and chitosan oligosaccharide. The invention also provides a preparation method of the nasal nano preparation brain targeting delivery system. Firstly, preparing nano-particle freeze-dried powder, and secondly, stirring the freeze-dried powder and chitosan oligosaccharide in isotonic normal saline before use to obtain the nasal preparation with good membrane permeability. The system has simple preparation method, can improve the hydrophobicity of the small molecular drug, reduce the toxicity and enhance the neuroprotective effect; no carrier, no biodegradation problem and accumulative toxicity, high drug loading rate up to more than 25%, good transdermal absorption after chitosan oligosaccharide modification, and high-targeting delivery of the drug into brain. The dosage form has the advantages of nasal drop, spray, etc., simple operation, convenient administration for patients taking medicine for a long time, and good application prospect in the treatment of nervous system diseases. |
| priorityDate | 2019-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.